Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isarna starts first-in-human ISTH0036 Phase I trial to treat glaucoma
Around 24-30 patients will be enrolled in the first-in-human trial, which will be conducted at the University Hospitals of Mainz and Tuebingen in Germany. The trial will evaluate
Around 24-30 patients will be enrolled in the first-in-human trial, which will be conducted at the University Hospitals of Mainz and Tuebingen in Germany. The trial will evaluate
The US Food and Drug Administration (FDA) has granted approval for Sandoz’s Glatopa, the first generic version of Teva’s Copaxone (glatiramer acetate injection) 20mg/ml one-time-daily multiple sclerosis (MS)
The deal aims at the development of a joint project, based on new findings by professor Aaron Ciechanover, Dr Gila Maor and professor Ofer Binah, that can potentially
As part of the deal, BMS has transferred full commercialization and manufacturing operational responsibilities to Lilly. The companies’ decision comes after a 14-year successful collaboration, which includes ImClone,
The Takeda-CiRA (T-CiRA) joint program is designed to expedite multiple research projects for drug discovery and cell therapy using iPS cells. As part of the deal, CiRA director
ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A for control and prevention of bleeding episodes, perioperative management as well as
As part of the deal, Immunocore will conduct a Phase Ib/II trial combining MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100 to treat patients with metastatic melanoma. MEDI4736 and/or
Both the firms will advance the development candidate through IND-enabling studies to prepare for the initiation of clinical trials. As part of the deal, BMS has the first
As part of the amended deal, certain existing milestones and funding obligations have been revised, and the deal has been expanded to include select pre-commercialization activities. In total,
TrojanTec is a discovery research and development company affiliated with UK’s Imperial College London. TR-1 is a potent and specific replacement therapy of wild type p53/p21, which represents